Actively Recruiting
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
Led by Beth Israel Deaconess Medical Center · Updated on 2025-10-28
120
Participants Needed
1
Research Sites
322 weeks
Total Duration
On this page
Sponsors
B
Beth Israel Deaconess Medical Center
Lead Sponsor
N
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The study is being conducted to learn why some patients with Benign Prostatic Hyperplasia (BPH) do not respond to a commonly used treatment drug, Finasteride. The hope is to find ways to predict which patients will not respond to Finasteride so that, in the future, these patients can be identified prior to offering this treatment and they can be offered alternative treatment strategies in its place. The aim is to see if noninvasive techniques such as MRI can detect inflammation of the prostate to assist with early detection of those who will and who will not respond to Finasteride.
CONDITIONS
Official Title
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male (physiological)
- Age 50 years or older
- Eligible for treatment with 5-alpha reductase inhibitor therapy
- Presence of lower urinary tract symptoms caused by benign prostatic hyperplasia
- Prostate size larger than 40cc by digital rectal examination
- No prostate nodules, tenderness, or firmness
- Mildly elevated prostate-specific antigen (PSA) between 1.5 and 40 ng/ml
- Undergoing a clinically indicated prostate biopsy due to elevated PSA
You will not qualify if you...
- Diagnosis of any prostate cancer or precancerous prostate lesions
- Treatment with 5-alpha reductase inhibitors (Finasteride or Dutasteride) within 6 months before enrollment
- Current urinary tract infection
- Previous pelvic radiation therapy
- Previous treatment with demethylating drugs
- Diagnosis of multiple sclerosis, Alzheimer's, Parkinson's, or other neurological deficits
- Unable or unwilling to undergo MRI due to implants, claustrophobia, or other reasons
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Actively Recruiting
Research Team
Y
Yulia Mulugeta, BS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here